PITTSBURGH,July 25, 2025 (GLOBE NEWSWIRE) -Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) announced today that on July 24, 2025, Japan's July 24, 2025, Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for VYJUVEK ® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) from birth. VYJUVEK is the first genetically approved drug inJapandeveloped for the treatment of DEB, it aims to address the root cause of the disease. It delivers functional copies of the human COL7A1 gene to enable wound healing and sustained functional expression of collagen protein type VII upon re-dosing. The Japanese approval allows for dosing at home or in a medical facility, with the possibility of administration by patients or their relatives.
According to the MHLW approval, VYJUVEK is intended exclusively for use in patients diagnosed with dystrophic epidermolysis bullosa. Genetic testing is not required for treatment.
